Aberrant DNA methylation precedes loss of heterozygosity on chromosome 16 in chronic hepatitis and liver cirrhosis

Yae Kanai, Saori Ushijima, Hitoshi Tsuda, Michiie Sakamoto, Setsuo Hirohashi

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

The aim of this study was to examine the significance of aberrant DNA methylation, the participation of which in genetic instability is controversial, in hepatocarcinogenesis. The DNA methylation status of the region around the promoter of the E-cadherin tumor suppresser gene, which is located on 16q22.1, and the allelic status at the D16S421 locus, which is adjacent to the E-cadherin locus, were examined using microdissected liver specimens from 38 hepatocellular carcinoma (HCC) patients. Almost all of the non-cancerous liver tissues showed histological findings compatible with chronic hepatitis and cirrhosis, which are considered to be precancerous conditions. DNA hypermethylation was detected in 61% of the non-cancerous liver tissues. The incidence of DNA hypermethylation in the non-cancerous liver tissues of patients with HCCs also showing DNA hypermethylation (72%) was significantly higher than that of patients without DNA hypermethylation in their HCCs (53%, P<0.05). Loss of heterozygosity (LOH) at the D16S421 locus was detected in 35% of the non-cancerous liver tissues. The incidence of LOH in the non-cancerous liver tissues of patients with HCCs also showing LOH was 78%, whereas LOH was not detected in non-cancerous liver tissues of patients without LOH in their HCCs. Fifty-two percent of the non-cancerous liver tissues showed both or neither of DNA hypermethylation and LOH; the incidence of DNA hypermethylation alone in non-cancerous liver tissue was 41%. The incidence of LOH alone in non-cancerous liver tissue (7%) was significantly lower compared to those of the former two cases (P<0.0001). These data suggest that aberrant DNA methylation participates in the precancerous stage of hepatocarcinogenesis by preceding, or causing, LOH. Copyright (C) 2000 Elsevier Science Ireland Ltd.

Original languageEnglish
Pages (from-to)73-80
Number of pages8
JournalCancer Letters
Volume148
Issue number1
DOIs
Publication statusPublished - 2000 Jan 1
Externally publishedYes

Fingerprint

Chromosomes, Human, Pair 16
Loss of Heterozygosity
DNA Methylation
Chronic Hepatitis
Liver Cirrhosis
Liver
DNA
Incidence
Cadherins
Precancerous Conditions
Genetic Promoter Regions
Hepatocellular Carcinoma
Fibrosis

Keywords

  • Chronic hepatitis
  • DNA hypermethylation
  • E-cadherin
  • Hepatocellular carcinoma
  • Liver cirrhosis
  • Loss of heterozygosity

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

Aberrant DNA methylation precedes loss of heterozygosity on chromosome 16 in chronic hepatitis and liver cirrhosis. / Kanai, Yae; Ushijima, Saori; Tsuda, Hitoshi; Sakamoto, Michiie; Hirohashi, Setsuo.

In: Cancer Letters, Vol. 148, No. 1, 01.01.2000, p. 73-80.

Research output: Contribution to journalArticle

@article{da68fa621a3843efb524dfb0140a55c1,
title = "Aberrant DNA methylation precedes loss of heterozygosity on chromosome 16 in chronic hepatitis and liver cirrhosis",
abstract = "The aim of this study was to examine the significance of aberrant DNA methylation, the participation of which in genetic instability is controversial, in hepatocarcinogenesis. The DNA methylation status of the region around the promoter of the E-cadherin tumor suppresser gene, which is located on 16q22.1, and the allelic status at the D16S421 locus, which is adjacent to the E-cadherin locus, were examined using microdissected liver specimens from 38 hepatocellular carcinoma (HCC) patients. Almost all of the non-cancerous liver tissues showed histological findings compatible with chronic hepatitis and cirrhosis, which are considered to be precancerous conditions. DNA hypermethylation was detected in 61{\%} of the non-cancerous liver tissues. The incidence of DNA hypermethylation in the non-cancerous liver tissues of patients with HCCs also showing DNA hypermethylation (72{\%}) was significantly higher than that of patients without DNA hypermethylation in their HCCs (53{\%}, P<0.05). Loss of heterozygosity (LOH) at the D16S421 locus was detected in 35{\%} of the non-cancerous liver tissues. The incidence of LOH in the non-cancerous liver tissues of patients with HCCs also showing LOH was 78{\%}, whereas LOH was not detected in non-cancerous liver tissues of patients without LOH in their HCCs. Fifty-two percent of the non-cancerous liver tissues showed both or neither of DNA hypermethylation and LOH; the incidence of DNA hypermethylation alone in non-cancerous liver tissue was 41{\%}. The incidence of LOH alone in non-cancerous liver tissue (7{\%}) was significantly lower compared to those of the former two cases (P<0.0001). These data suggest that aberrant DNA methylation participates in the precancerous stage of hepatocarcinogenesis by preceding, or causing, LOH. Copyright (C) 2000 Elsevier Science Ireland Ltd.",
keywords = "Chronic hepatitis, DNA hypermethylation, E-cadherin, Hepatocellular carcinoma, Liver cirrhosis, Loss of heterozygosity",
author = "Yae Kanai and Saori Ushijima and Hitoshi Tsuda and Michiie Sakamoto and Setsuo Hirohashi",
year = "2000",
month = "1",
day = "1",
doi = "10.1016/S0304-3835(99)00316-X",
language = "English",
volume = "148",
pages = "73--80",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Aberrant DNA methylation precedes loss of heterozygosity on chromosome 16 in chronic hepatitis and liver cirrhosis

AU - Kanai, Yae

AU - Ushijima, Saori

AU - Tsuda, Hitoshi

AU - Sakamoto, Michiie

AU - Hirohashi, Setsuo

PY - 2000/1/1

Y1 - 2000/1/1

N2 - The aim of this study was to examine the significance of aberrant DNA methylation, the participation of which in genetic instability is controversial, in hepatocarcinogenesis. The DNA methylation status of the region around the promoter of the E-cadherin tumor suppresser gene, which is located on 16q22.1, and the allelic status at the D16S421 locus, which is adjacent to the E-cadherin locus, were examined using microdissected liver specimens from 38 hepatocellular carcinoma (HCC) patients. Almost all of the non-cancerous liver tissues showed histological findings compatible with chronic hepatitis and cirrhosis, which are considered to be precancerous conditions. DNA hypermethylation was detected in 61% of the non-cancerous liver tissues. The incidence of DNA hypermethylation in the non-cancerous liver tissues of patients with HCCs also showing DNA hypermethylation (72%) was significantly higher than that of patients without DNA hypermethylation in their HCCs (53%, P<0.05). Loss of heterozygosity (LOH) at the D16S421 locus was detected in 35% of the non-cancerous liver tissues. The incidence of LOH in the non-cancerous liver tissues of patients with HCCs also showing LOH was 78%, whereas LOH was not detected in non-cancerous liver tissues of patients without LOH in their HCCs. Fifty-two percent of the non-cancerous liver tissues showed both or neither of DNA hypermethylation and LOH; the incidence of DNA hypermethylation alone in non-cancerous liver tissue was 41%. The incidence of LOH alone in non-cancerous liver tissue (7%) was significantly lower compared to those of the former two cases (P<0.0001). These data suggest that aberrant DNA methylation participates in the precancerous stage of hepatocarcinogenesis by preceding, or causing, LOH. Copyright (C) 2000 Elsevier Science Ireland Ltd.

AB - The aim of this study was to examine the significance of aberrant DNA methylation, the participation of which in genetic instability is controversial, in hepatocarcinogenesis. The DNA methylation status of the region around the promoter of the E-cadherin tumor suppresser gene, which is located on 16q22.1, and the allelic status at the D16S421 locus, which is adjacent to the E-cadherin locus, were examined using microdissected liver specimens from 38 hepatocellular carcinoma (HCC) patients. Almost all of the non-cancerous liver tissues showed histological findings compatible with chronic hepatitis and cirrhosis, which are considered to be precancerous conditions. DNA hypermethylation was detected in 61% of the non-cancerous liver tissues. The incidence of DNA hypermethylation in the non-cancerous liver tissues of patients with HCCs also showing DNA hypermethylation (72%) was significantly higher than that of patients without DNA hypermethylation in their HCCs (53%, P<0.05). Loss of heterozygosity (LOH) at the D16S421 locus was detected in 35% of the non-cancerous liver tissues. The incidence of LOH in the non-cancerous liver tissues of patients with HCCs also showing LOH was 78%, whereas LOH was not detected in non-cancerous liver tissues of patients without LOH in their HCCs. Fifty-two percent of the non-cancerous liver tissues showed both or neither of DNA hypermethylation and LOH; the incidence of DNA hypermethylation alone in non-cancerous liver tissue was 41%. The incidence of LOH alone in non-cancerous liver tissue (7%) was significantly lower compared to those of the former two cases (P<0.0001). These data suggest that aberrant DNA methylation participates in the precancerous stage of hepatocarcinogenesis by preceding, or causing, LOH. Copyright (C) 2000 Elsevier Science Ireland Ltd.

KW - Chronic hepatitis

KW - DNA hypermethylation

KW - E-cadherin

KW - Hepatocellular carcinoma

KW - Liver cirrhosis

KW - Loss of heterozygosity

UR - http://www.scopus.com/inward/record.url?scp=0033988602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033988602&partnerID=8YFLogxK

U2 - 10.1016/S0304-3835(99)00316-X

DO - 10.1016/S0304-3835(99)00316-X

M3 - Article

VL - 148

SP - 73

EP - 80

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -